Antiplatelet therapies: Platelet GPIIb/IIIa antagonists and beyond

被引：11
作者：
Mousa, SA [1 ]
机构：
[1] Albany Coll Pharm, Albany, NY 12208 USA
来源：
CURRENT PHARMACEUTICAL DESIGN | 2003年 / 9卷 / 28期
关键词：
D O I：
10.2174/1381612033453893
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Cardiovascular and cerebrovascular diseases continue to be leading causes of death throughout the world. Blood platelets play a pivotal role not only in haemostasis but also in the pathogenesis of thrombosis and atherosclerosis, platelet aggregation being an essential step in the formation of either an effective haemostatic plug or an intravascular thrombus. The benefits of various antiplatelet therapies ranging from aspirin, ticlopidine, Clopidogrel, and intravenous platelet GPIIb/IIIa antagonists in various thromboembolic disorders are well documented. Despite of the success of intravenous acute GPIIb/IIIa blockade when given in conjunction with heparin, chronic oral GPIIb/IIIa antagonists with or without aspirin failed in various cardiovascular settings. This review highlights the role of the various antiplatelet therapies in thrombotic disorders as well as future directions.
引用
收藏
页码：2317 / 2322
页数：6
相关论文
共 48 条
  • [1] Akkerhuis M, 1999, CIRCULATION, V100, P292
  • [2] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
    ALTMAN, R
    CARRERAS, L
    DIAZ, R
    FIGUEROA, E
    PAOLASSO, E
    PARODI, JC
    CADE, JF
    DONNAN, G
    EADIE, MJ
    GAVAGHAN, TP
    OSULLIVAN, EF
    PARKIN, D
    RENNY, JTG
    SILAGY, C
    VINAZZER, H
    ZEKERT, F
    ADRIAENSEN, H
    BERTRANDHARDY, JM
    BRAN, M
    DAVID, JL
    DRICOT, J
    LAVENNEPARDONGE, E
    LIMET, R
    LOWENTHAL, A
    MORIAU, M
    SCHAPIRA, S
    SMETS, P
    SYMOENS, J
    VERHAEGHE, R
    VERSTRAETE, M
    ATALLAH, A
    BARNETT, H
    BATISTA, R
    BLAKELY, J
    CAIRNS, JA
    COTE, R
    CROUCH, J
    EVANS, G
    FINDLAY, JM
    GENT, M
    LANGLOIS, Y
    LECLERC, J
    NORRIS, J
    PINEO, GF
    POWERS, PJ
    ROBERTS, R
    SCHWARTZ, L
    SICURELLA, J
    TAYLOR, W
    THEROUX, P
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100
  • [3] Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity
    Amirkhosravi, A
    Amaya, M
    Desai, H
    Francis, JL
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2002, 13 (06) : 505 - 512
  • [4] [Anonymous], 1988, LANCET, V2, P349
  • [5] Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial
    Ault, KA
    Cannon, CP
    Mitchell, J
    McCahan, J
    Tracy, RP
    Novotny, WF
    Reimann, JD
    Braunwald, E
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (03) : 634 - 639
  • [6] The impact of thrombopoietin on clinical practice
    Basser, R
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (05) : 369 - 377
  • [7] Bazzino O, 1998, NEW ENGL J MED, V338, P1498
  • [8] Bazzino O, 1998, NEW ENGL J MED, V338, P1488
  • [9] Bednar RA, 1998, J PHARMACOL EXP THER, V285, P1317
  • [10] Small peptide radiopharmaceuticals in the imaging of acute thrombus
    Blum, JE
    Handmaker, H
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (20) : 1815 - 1826
12345